MedTrace Logo

Bupivacaine Levels in Liver Resection Patients

NCT03145805 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-03-24

No results posted yet for this study

Summary

Bupivacaine is a local anesthetic commonly used to manage postoperative pain. Liver resection patients typically have an epidural catheter placed preoperatively through which they receive a continuous infusion of bupivacaine and hydromorphone for up to 5 days postoperatively. The liver metabolizes bupivacaine, and produces proteins that bind with bupivacaine to take it out of circulation and thereby reduce its toxicity. Because a portion of the liver is being removed due to pre-existing liver disease, investigators hypothesize that liver resection patients have an impaired ability to clear bupivacaine from circulation that may increase their susceptibility to bupivacaine toxicity. To assess this, investigators will measure free and bound bupivacaine in liver resection patients postoperatively to determine whether bupivacaine reaches toxic levels. Investigators will also quantify binding protein levels to determine if these levels are reduced after surgery, which could contribute to the elevated bupivacaine levels in these patients. Finally, investigators will monitor patients for signs and symptoms associated with bupivacaine toxicity.

Conditions

  • Hepatectomy
  • Analgesia, Epidural

Sponsors & Collaborators

  • Jessica Burjorjee, MD, FRCPC

    lead OTHER

Principal Investigators

  • Jessica Burjorjee, MD, FRCPC · Queen's University/Kingston General Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-19
Primary Completion
2020-02-15
Completion
2020-02-15

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03145805 on ClinicalTrials.gov